SmarTrend identified a Downtrend for Discovery Laboratories (NASDAQ:DSCO) on January 21, 2011 at $3.17. In approximately 3 months since that trend was identified, Discovery Laboratories has fallen 43.3% as of Thursday's closing price of $1.80. In the past 52 weeks, shares of Discovery Laboratories have traded between a low of $1.71 and a high of $9.30 and are now at $1.80, which is 5% above that low price. Discovery Laboratories is currently below its 50-day moving average of $2.26 and below its 200-day moving average of $3.07. Look for these moving averages to decline to confirm the company's downward momentum. In the last five trading sessions, the 50-day MA has fallen 3.22% while the 200-day MA has slid 0.84%. SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any changes in momentum for shares of Discovery Laboratories
Discovery Laboratories, Inc. (Nasdaq: DSCO) reports positive data from a study using aerosolized KL4 surfactant demonstrated a significant improvement in lung function and survival when treating Acute Lung Injury (ALI) in a well-established preclinical model of this severe respiratory condition.
From the release: The following study was presented: Aerosolized KL4 Surfactant Improves Gas Exchange and Survival in Spontaneously Breathing Piglets With HCl Induced Acute Lung Injury; Lampland, et al.
: Discovery Labs moves forward on Surfaxin approval
bewegt sich vorwärts auf Surfaxin Genehmigung !!
Discovery Laboratories said Wednesday that it remains on track with getting its respiratory disease drug, Surfaxin, ready for final review by the Food and Drug Administration. The Warrington-based biotechnology company expects approval for the drug to come early next year.
The company also said Wednesday that it recorded a $3.8 million loss in the first quarter, an improvement from a $6.1 million loss a year ago thanks to income from the change in the value of stock warrants.
Discovery Labs said it ended the quarter with $27.7 million in cash and cash equivalents, and two financing agreements that it could use to raise additional capital.
Discovery has been working closely with the FDA on approval for Surfaxin to treat respiratory distress syndrome in premature infants. It's getting ready to perform extra clinical trials on the drug to answer questsions from the federal agency. It expects to complete those tests later this year.